Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-09 5:08 pm Sale |
2023-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
Artal Participations S.a r.l | 0 0.000% |
-15,066,043 (Position Closed) |
Filing History |
| 2023-10-10 11:35 am Purchase |
2021-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
HOPU Reunion Co Ltd | 38,952,409 8.900% |
38,952,409 (New Position) |
Filing History |
| 2023-09-25 5:24 pm Purchase |
2023-09-14 | 13G | Ambrx Biopharma Inc. AMAM |
Paradigm BioCapital Advisors LP | 25,172,784 5.700% |
25,172,784 (New Position) |
Filing History |
| 2023-06-28 4:45 pm Purchase |
2023-06-27 | 13D | Ambrx Biopharma Inc. AMAM |
Darwin Global Management, Ltd. | 116,820,452 27.500% |
37,688,441 (+47.63%) |
Filing History |
| 2023-05-25 4:39 pm Unchanged |
2023-05-23 | 13D | Ambrx Biopharma Inc. AMAM |
Darwin Global Management, Ltd. | 79,132,011 20.500% |
0 (Unchanged) |
Filing History |
| 2023-04-27 4:05 pm Sale |
2023-04-24 | 13G | Ambrx Biopharma Inc. AMAM |
Commodore Capital LP | 31,181,983 8.100% |
-4,518,017 (-12.66%) |
Filing History |
| 2023-03-16 4:05 pm Purchase |
2023-03-06 | 13G | Ambrx Biopharma Inc. AMAM |
SHAW D E & CO L P | 22,050,000 8.200% |
22,050,000 (New Position) |
Filing History |
| 2023-03-13 4:00 pm Purchase |
2023-03-03 | 13G | Ambrx Biopharma Inc. AMAM |
Cormorant Asset Management LP | 52,500,000 17.730% |
36,145,298 (+221.01%) |
Filing History |
| 2023-03-08 10:49 am Purchase |
2023-03-06 | 13D | Ambrx Biopharma Inc. AMAM |
Darwin Global Management, Ltd. | 79,132,011 26.400% |
26,040,588 (+49.05%) |
Filing History |
| 2023-03-03 4:10 pm Purchase |
2023-02-23 | 13G | Ambrx Biopharma Inc. AMAM |
Commodore Capital LP | 35,700,000 13.200% |
9,450,000 (+36.00%) |
Filing History |
| 2023-03-03 4:05 pm Purchase |
2023-02-21 | 13G | Ambrx Biopharma Inc. AMAM |
Commodore Capital LP | 26,250,000 9.700% |
26,250,000 (New Position) |
Filing History |
| 2023-02-27 4:05 pm Purchase |
2023-02-16 | 13G | Ambrx Biopharma Inc. AMAM |
Venrock Healthcare Capital Partners III L.P. | 26,740,000 9.900% |
26,740,000 (New Position) |
Filing History |
| 2023-02-14 4:02 pm Sale |
2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
HBM BIOVENTURES CAYMAN LTD | 8,400,000 3.100% |
-8,456,567 (-50.17%) |
Filing History |
| 2023-02-14 3:12 pm Sale |
2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
Cormorant Asset Management LP | 16,354,702 6.050% |
-911,442 (-5.28%) |
Filing History |
| 2023-02-14 09:30 am Purchase |
2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
Darwin Global Management, Ltd. | 53,091,423 19.600% |
2,450,000 (+4.84%) |
Filing History |
| 2023-02-10 7:21 pm Unchanged |
2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
Artal Participations S.a r.l | 15,066,043 5.600% |
0 (Unchanged) |
Filing History |
| 2023-02-09 10:54 am Sale |
2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
ADAGE CAPITAL PARTNERS GP LLC | 7,191,037 2.660% |
-7,000,000 (-49.33%) |
Filing History |
| 2023-02-09 08:23 am Sale |
2023-02-09 | 13G | Ambrx Biopharma Inc. AMAM |
FMR CORP | 18,872,448 6.981% |
-7,936,866 (-29.60%) |
Filing History |
| 2022-12-19 08:30 am Purchase |
2022-12-09 | 13G | Ambrx Biopharma Inc. AMAM |
Darwin Global Management, Ltd. | 50,641,423 18.700% |
50,641,423 (New Position) |
Filing History |
| 2022-03-10 09:48 am Sale |
2022-03-09 | 13G | Ambrx Biopharma Inc. AMAM |
FMR CORP | 26,809,314 10.683% |
-175,861 (-0.65%) |
Filing History |